Novel Therapeutic Agents in Waldenström’s Macroglobulinemia

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström’s macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and hist...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ghobrial, Irene M., Leleu, Xavier, Azab, Abdel Kareem, Runnels, Judith, Jia, Xiaoying, Ngo, Hai, Melhem, Molly, Azab, Feda, Sacco, Antonio, Quang, Phong, Burwick, Nicholas, Moreau, Anne-Sophie, Husu, Emanuel, Farag, Mena, Roccaro, Aldo
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3133646/
https://ncbi.nlm.nih.gov/pubmed/19362982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLM.2009.n.022
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars